New hydrogel stem cell treatment repairs injured brain tissue in mice
A new ‘hybrid’ hydrogel, which allows clinicians to safely deliver stem cells to the site of a brain injury in mice, has been developed by researchers from the University of Melbourne and the Australian National University. A hydrogel…
Imagion receives 2nd CSIRO Federal Government grant for prostate cancer project
Posted: 2 March 2023 Imagion Biosystems Limited, a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to announce that it has qualified for a second grant of $50,000 under the Entrepreneurs’ Programme of…
Peter MacCallum Cancer Centre and Cartherics Announce Collaboration to Develop Autologous CAR-T Cell Therapy for Ovarian Cancer
Posted: 1 March 2023 Peter MacCallum Cancer Centre (“Peter Mac”) and Cartherics Pty Ltd (“Cartherics”) announced they have entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-004) for the treatment…
Investing in a stronger, healthy region
Posted: 24 February 2023 Australia will invest in high-quality health programs across the Pacific and Southeast Asia as part of the Partnerships for a Healthy Region initiative, a new five-year program to improve health outcomes and promote regional…
Burnet welcomes announcement of regional health investment package
Posted: 24 February 2023 Burnet Institute has welcomed the Australian government’s announcement of an investment package that aims to help build a stronger and more resilient Asia-Pacific. Foreign Minister Penny Wong and Minister for International Development and the…
First Gene Therapy for Hemophilia B, CSL’s HEMGENIX®, Approved by the European Commission
Posted: 24 February 2023 Global biotechnology leader CSL (ASX: CSL) today announced that the European Commission has granted conditional marketing authorization (CMA) for HEMGENIX® (etranacogene dezaparvovec), the first and only one-time gene therapy for the treatment of severe and moderately severe…
Firebrick Pursues Development of Nasodine for Use in Children
Posted: 23 February 2023 Firebrick Pharma announced plans to develop Nasadine Nasal Spray for use in children as well as adults. The plans were outlined in a Paediatric Investigation Plan (PIP) that was filed with the European Medicines…
Clinical program with the Lambert Initiative Expands to include Avecho’s Oral Cannabidiol
Posted: 22 February 2023 Avecho Biotechnology Limited has today announced that its ongoing collaboration with leading Australian research group for cannabinoid therapeutics, the Lambert Initiative at the University of Sydney, will expand to include a series of clinical…
Monash Health’s Victorian Heart Hospital officially launches
Posted: 21 February 2023 The latest addition to the Monash Health group of hospitals was opened. The Victorian Heart Hospital was officially launched by the Victorian Premier Daniel Andrews and Minister for Health Mary-Anne Thomas. In partnership…
Medication for potential treatment of anxiety disorders and postpartum depression to progress to next stage of clinical trials
Posted: 21 February 2023 A unique drug delivery technology designed to enable the oral administration of certain therapeutics with low oral bioavailability has reached another exciting milestone with ‘LYT-300’ (oral allopregnanolone) set to enter a placebo-controlled, Phase 2a,…
Bio Connections Australia
Posted: 20 February 2023 Event: 24 July 2023 OVERVIEW Returning for 2023, Bio Connections Australia will take place on the 24th July 2023 at Crown, Melbourne. For 2023, we look forward to bringing together a diverse mix of…
An Unfinished Life: The True Impact of Antibiotic Resistance
Posted: 17 February 2023 Event: 14 March 2023 Internationally acclaimed documentary, Salt in my Soul, is coming to Melbourne in March as part of a nationwide mission to raise awareness for antibiotic resistance. Screenings are followed by interactive…
